Purpose: In numerous epidemiological studies, omega-3 polyunsaturated fatty acids (PUFAs) have been associated with a decreased risk of age-related macular degeneration (AMD). Beyond their structural, functional and neuroprotective roles, omega-3 PUFAs may favour the retinal accumulation of lutein and zeaxanthin and thus increase macular pigment optical density (MPOD). We examined the associations of MPOD with plasma omega-3 PUFAs in subjects with family history of AMD. Methods: The Limpia study is a double-blind, placebo-controlled, prospective randomized clinical trial performed in 120 subjects. Subjects with at least one parent treated for neovascular AMD, aged 40-70, with a best corrected visual acuity (BCVA) >20/25, free of late AMD and other major eye conditions and with no use of supplement containing lutein or zeaxanthin the preceding year were recruited in Bordeaux and Dijon, France. At baseline, MPOD within 1°of eccentricity was measured by modified Heidelberg retinal analyser (Heidelberg, Germany) and plasma omega-3 PUFAs by gas chromatography. Medical history and lifestyle data were collected from a standardized questionnaire. Associations of MPOD with plasma omega-3 PUFAs were assessed at the baseline examination, using mixed linear models adjusted for age, gender, centre, body mass index, smoking, plasma high-density lipoprotein (HDL) cholesterol and lutein+zeaxanthin. Results: After multivariate adjustment, high MPOD was significantly associated with higher level of plasma docosapentaenoic acid (DPA) (b = 0.029, 95% CI: 0.003, 0.055; p = 0.03). Plasma alpha linolenic, eicosapentaenoic and docosahexaenoic acids were not significantly associated with MPOD. Conclusion: In the Limpia study, high MPOD within 1°was significantly associated with higher plasma levels of omega-3 DPA.
Introduction
The macular pigment consists of two major carotenoids, lutein and zeaxanthin (Bone et al. 1993; Landrum & Bone 2001 ). Lutein and zeaxanthin must be obtained from dietary sources such as green leafy vegetables or orange and yellow fruits and vegetables (Calvo 2005; Thurnham 2007 ). Oral supplementation of lutein and zeaxanthin and high dietary intake of these xanthophylls are known to increase their concentrations in plasma and, in turn, of their specific accumulation within the macula (Mares et al. 2006; Richer et al. 2007; Trieschmann et al. 2007; Connolly et al. 2010; Delyfer et al. 2012; Ma et al. 2012a,b; Arnold et al. 2013; Yoshizako et al. 2016) . Macular pigment absorbs blue light and acts as a filter that attenuates phototoxic damages of the retina from blue light exposure (Roberts et al. 2009 ). It also works as an antioxidant by defending rod outer segment membranes from oxidative stress (Krinsky et al. 2003) and has anti-inflammatory properties (Kijlstra et al. 2012) . Inflammation and oxidative stress are known to be involved in the pathogenesis of AMD (Donoso et al. 2006; Bazan 2009 ). Epidemiological studies have suggested that subjects with high dietary intakes and high plasma levels of lutein and zeaxanthin have a reduced risk of AMD (Seddon et al. 1994 (Seddon et al. , 2010 Mares-Perlman et al. 2001; Delcourt et al. 2006; Mares et al. 2006; Ma et al. 2012a,b) , the leading cause of blindness in industrialized countries (Resnikoff et al. 2004; Lim et al. 2012) . Recently, the clinical trial AREDS2 suggested that lutein and zeaxanthin could be more appropriate carotenoids in oral supplementation for AMD patients (Age-Related Eye Disease Study 2 Research 2013; Chew et al. 2014) .
Macular pigment accumulation may rely on specific carotenoid-binding proteins, but the exact mechanisms remain unclear (Borel et al. 2011; Bernstein et al. 2016 ). Lutein and zeaxanthin are lipid soluble, and their metabolism is strongly linked to lipid metabolism (Kijlstra et al. 2012 ). Long-chain omega-3 polyunsaturated fatty acids (LC PUFA) are other nutrients abundant in the human retina where they play structural, functional and neuroprotective roles (SanGiovanni & Chew 2005) . In AMD, numerous studies have reported a decreased risk for AMD in subjects with high dietary intake (Seddon et al. 2001; Chong et al. 2008; SanGiovanni et al. 2009; Merle et al. 2011; Reynolds et al. 2013 ) and circulating levels (Merle et al. 2013a,b; Merle et al. 2014 ) of LC omega-3 PUFAs. Among their protective mechanisms, it has been suggested that LC omega-3 PUFAs may favour the retinal accumulation of lutein and zeaxanthin and thus increase MPOD (Mares et al. 2006; Johnson et al. 2008 ). In the PIMAVOSA study, we reported that MPOD was associated not only with plasma lutein and zeaxanthin but also with LC omega-3 PUFAs in a population of healthy volunteers (Delyfer et al. 2012) . Because macular pigment plays a pivotal role against oxidative stress damage and inflammation within the retina, identification of the mechanisms underlying the specific accumulation of xanthophylls represents a key step towards a better understanding of macular disease.
In this study, we assess the associations of MPOD with plasma biomarkers of LC omega-3 PUFAs status in a population with a family history of AMD.
Materials and Methods

Study sample
The LIMPIA (Lutein Influence on Macula of Persons Issued from AMD parents) study is a double-masked, parallel, prospective randomized clinical trial (ClinicalTrials.gov number NCT01269697) to assess the efficiency of lutein and zeaxanthin and omega-3 fatty acids daily oral supplementation for increasing MPOD and plasma lutein and zeaxanthin. This study focuses only on crosssectional analyses at the baseline examination.
Eligible criteria
Participants, aged 40-70 years at baseline, were required to have at least one parent (father or mother or both) treated for neovascular AMD either at Bordeaux or Dijon Hospitals and to have a visual acuity (VA) no worse than 20/25. In addition, both eyes of each participant had to be free from any sign of AMD, or other eye disease, which would have made AMD and VA measurements unlikely or difficult (i.e. severe glaucoma, myopia superior or equal to À6 dioptres, other severe retinopathy). Participants with history of cataract surgery or anterior segment opacities (cataract, corneal dystrophy), participants who had used a nutritional supplement during the previous year or judged to be non-compliant were excluded.
The research followed the tenets of the Declaration of Helsinki, and all participants gave written consent for participation in the study. Baseline eye examinations included, for both eyes, measures of VA refraction, slit-lamp biomicroscopy and, after pupil dilatation with eye drops containing 0.5% tropicamide and 2.5% phenylephrine, colour retinal photographs and MPOD measurement. AMD status was assessed by fundus examination, colour retinal photographs and spectraldomain optical coherence tomography (SD-OCT, Spectralis, Heidelberg Engineering, Germany).
Macular pigment optical density (MPOD) measurements were obtained with the modified Heidelberg Retina Angiograph (HRA) (Heidelberg Engineering, Heidelberg, Germany). Subjects were positioned in front of the tabletop and were instructed to look straight ahead and to remain steady. Autofluorescence images (20°) were then obtained at excitation wavelengths of 488 and 514 nm of the posterior pole, with a highpass filter transmitting at a wavelength >530 nm. Macular pigment optical density (MPOD) was quantified by calculating an MPOD map and comparing foveal and parafoveal autofluorescence at 488 and 514 nm. Density maps were processed to estimate MPOD within a circle centred on the fovea at different degrees of eccentricities (0.5, 1, 2 and 6°), using the software provided by the manufacturer of the device. Macular pigment optical density (MPOD) was expressed in optical density units. Macular pigment optical density (MPOD) measurements were performed in each centre by a single examiner.
Blood samples measurements
Plasma lipids (excluding fatty acids) were analysed from fasting blood samples collected at baseline using routine enzymatic techniques.
Plasma lutein and zeaxanthin measurements were performed at DSM Nutritional Products (Kaiseraugst, Switzerland). Concentrations of lutein (sum of all E and Z isomers) and zeaxanthin (sum of all E and Z isomers) were determined by normal-phase HPLC using dedicated analytical methods as described previously (Merle et al. 2013b) . Plasma lutein and zeaxanthin were expressed in lM.
Fatty acid measurements were performed in the Department of Nutrition Metabolism and Health at the French Institute for Fats and Oils in Bordeaux, France (ITERG). Omega-3 PUFAs [alpha linolenic (ALA), eicosapentaenoic (EPA), docosapentaenoic (DPA) and docosahexaenoic acids (DHA)] and other fatty acids from plasma phosphatidylcholine were measured by gas chromatography according to an adaptation of the method previously described (Merle et al. 2013a) . Fatty acids were expressed in % of total fatty acids.
Covariates
Age, gender, body mass index [BMI, weight/height² (kg/m²)] and smoking (ever smokers vs. never smokers) were collected through face-to face standardized interview at baseline examination.
Statistical analysis
Baseline characteristics were displayed as n (%) for categorical variables and mean AE SD for continuous variables (Table 1) .
Associations of MPOD with sociodemographic, behavioural and plasma lipids and carotenoids were analysed using mixed linear regression models with the individual eye as the unit of analysis. This model allows taking into account data for both eyes and their intra-individual correlation. The association of each characteristic with MPOD was assessed independently using a univariate model (non-adjusted model). Variables retained in the final multivariate model were factors associated with MPOD in this study (p univariate <0.20) . Multivariate model includes age (years), sex (male/female), centre (Bordeaux/Dijon), BMI (kg/m²), smoking (never smokers vs. ever smokers), HDL cholesterol (mM) and lutein + zeaxanthin (lM) ( Table 2) .
Associations between MPOD and plasma fatty acids were assessed using a multivariate mixed linear regression as described above. Each fatty acid was analysed in a separate model (Table 3 and Fig. 1) .
Total omega-3 PUFAs are the sum of ALA, EPA, DPA and DHA, and LC omega-3 PUFAs are the sum of EPA, DPA and DHA.
For all analyses, associations were considered significant at p < 0.05. All statistical analyses were performed using SAS software (SAS, version 9.3; SAS Institute Inc., Cary, NC, USA).
Results
Characteristics of the population
Among 120 subjects included in the LIMPIA study, 115 (227 eyes) had complete ophthalmic, plasma and socio-demographic and behavioural baseline data for our analyses. Table 1 shows socio-demographic, behavioural, plasma and MPOD characteristics. Mean age was 56.7 (AE6.5) years, 71.6% were women and 43.4% had never smoked. Mean of BMI was 24.8 (AE4.5) kg/m² and mean of MPOD was 0.56 (AE0.16) optical density units.
Associations of MPOD with sociodemographic and behavioural characteristics and plasma lipids and carotenoids As shown in Table 2 , high MPOD was significantly associated with a lower BMI (p = 0.001), higher plasma lutein + zeaxanthin (p = 0.03) and ever smokers tended to have lower MPOD (p = 0.06) than never smokers. In the final multivariate model, only BMI and smoking remained significantly As displayed in Fig. 1 , high MPOD within 1°was significantly associated with a higher level of plasma DPA (b = 0.029, 95%CI: 0.003, 0.055; p = 0.03). Plasma levels of ALA, EPA and DHA were not significantly associated with MPOD within 1°. We also explored whether MPOD within 0.5, 2 and 6 degrees of eccentricity were associated with plasma DPA. After multivariate adjustment, we found a significant association of MPOD within 2°with plasma levels of DPA (b = 0.0191, 95% CI: 0.0002, 0.0380; p = 0.048). Results for 0.5 and 6°were in the same direction but did not reach statistical significance (b = 0.0296, 95% CI: À0.004, 0.0596; p = 0.05 and b = 0.0074 95% CI: À0.008, 0.0156; p = 0.08, respectively). Table 3 displays multivariate associations between MPOD and other plasma fatty acids. No other fatty acid was significantly associated with MPOD in our study.
Discussion
In the present study, we showed that high plasma levels of DPA were specifically associated with high MPOD within 1°of eccentricity in subjects with family history of AMD. Total omega-3 and total LC omega-3 PUFAs, as well as other individual omega-3 PUFAs (ALA, EPA and DHA), showed similar trends but did not reach statistical significance. Macular pigment optical density (MPOD) was also associated with smoking status and lower BMI.
The present study confirms the association between plasma DPA and MPOD reported by the PIMAVOSA study in 2012 (Delyfer et al. 2012) . While the PIMAVOSA study included healthy subjects aged 20-60 years who were free of eye diseases, the Limpia study enrolled older subjects, aged 40-70 years, with family history of AMD. Those two populations may have different genetic background as well as environmental factors such as smoking and diet; nevertheless, the associations between plasma fatty acids and MPOD remained similar. Epidemiological studies have shown that high LC omega-3 PUFAs measured in both diet (Seddon et al. 2001; SanGiovanni & Chew 2005; Chong et al. 2008; SanGiovanni et al. 2009; Merle et al. 2011; Reynolds et al. 2013) and blood (Merle et al. 2013a (Merle et al. , 2014 were associated with a decreased risk of AMD. A low concentration of macular pigment in the retina may increase the risk of macular degeneration (MaresPerlman et al. 2001; Delcourt et al. 2006; Ma et al. 2012a,b; Meyers et al. 2013) . Associations between MPOD and omega-3 PUFAs have not been extensively explored. To our knowledge, two studies have investigated the associations of macular pigment with plasma omega-3 PUFAs and they found partially consistent results. The PIMAVOSA study (Delyfer et al. 2012) revealed that high plasma levels of EPA, DPA, total omega-3 PUFAs and total LC omega-3 PUFAs were significantly correlated with high MPOD in a homogeneous population of healthy volunteers aged 20-60 years. This study reported a stronger correlation with DPA than with other omega-3 PUFAs (DPA: r = 0.32, p = 0.0007; EPA: r = 0.21, p = 0.04; DHA: r = 0.14, p = 0.16), and the correlation with DHA was not significant. The Montrachet population-based study reported no significant correlation between total omega-3 PUFAs and MPOD (r = À0004, p = 0.46) (Alassane et al. 2016), but did not explore specific associations with individual omega-3 PUFAs. In particular, no results were provided for DPA.
The mechanisms by which omega-3 PUFAs may increase MPOD may include their effects on the transport and uptake of xanthophylls into the macula. A supplementation of LC omega-3 PUFAs is known to modify circulating lipoprotein subclasses by increasing HDL and low-density lipoprotein (LDL) subfractions (Thomas et al. 2004 ). Lutein and zeaxanthin, being fat-soluble micronutrients, are carried by plasma lipoproteins and mainly HDL (Clevidence & Bieri 1993; Tyssandier et al. 2002) . Thus, it is possible that the increase in HDL lipoproteins, due to omega-3 PUFAs intake, favours transport and delivery of xanthophylls into the macula. LC omega-3 PUFAs might also affect macular pigment through interaction with xanthophyll-binding proteins and thus influence the accumulation of lutein and zeaxanthin in the retina (Li et al. 2010) . Johnson et al. (2008) previously published that although DHA supplementation could influence MPOD distribution, it did not increase significantly the total MPOD value. In the present study, while there were no significant associations of plasma DHA and EPA with MPOD, a significant association was found between MPOD and plasma DPA. Docosapentaenoic acid (DPA) is a metabolic intermediary between EPA and DHA and is the second most abundant LC omega-3 PUFA in the retina (Liu et al. 2010) . Docosapentaenoic acid (DPA) is also known to be a precursor of verylong-chain omega-3 PUFAs (VLC). Very-long-chain omega-3 PUFAs (VLC) are found in restricted mammalian tissues such as retina, testes, thymus and brain. Unlike DHA or EPA and their precursors, VLC omega-3 PUFAs are not present in a normal human diet (McMahon & Kedzierski 2010 ), but they can be synthetized from precursors such as DPA via a specific biochemical pathway (Liu et al. 2010 ). Very-long-chain omega-3 PUFAs (VLC) appear to be important for retinal health. Indeed, low levels of VLC omega-3 PUFAs and alterations in their biosynthesis have been associated to retinal eye disease. In particular, defects in the elongation of the VLC fatty acids (ELOVL4) gene are associated with autosomal dominant Stargardt macular dystrophy (Bernstein et al. 2001; Zhang et al. 2001) . Moreover, Liu et al. (2010) observed a reduction in DPA, DHA and VLC omega-3 PUFAs in early and intermediate AMD retinas versus matched control retinas. Finally, VLC PUFAs status in the retina has been shown to be correlated to plasma status in their precursors (including DPA), suggesting that dietary intake of precursors may directly influence the retinal status in VLC PUFAs Fig. 1 . Associations between macular pigment optical density and plasma omega-3 PUFAs. The LIMPIA study (n = 115 subjects, n = 227 eyes).
Mixed linear regression models, beta for 1-SD increase in plasma fatty acid. Each fatty acid was analysed in a separate model. Long-chain omega-3: EPA+DPA+DHA; Total omega PUFAs = ALA+EPA+DPA+DHA. ALA = alpha linolenic acid, BMI = body mass index, CI = confidence interval, DHA = docosahexaenoic acid, DPA = docosapentaenoic acid, EPA = eicosapentaenoic acid, HDL = high-density lipoprotein, MPOD = macular pigment optical density, PUFA = polyunsaturated fatty acid. *Multivariate model is adjusted for age, sex, centre, BMI, smoking, plasma HDL cholesterol and plasma lutein + zeaxanthin.
retina, which, in turn, might influence the structure or function of the retina and favour the accumulation of macular pigment. This hypothesis would need to be tested in future studies. Despite the fact that imbalance between LC omega 6 and LC omega-3 PUFAs or saturated fatty acids (SFA) has been suggested as a potential risk factor for AMD, in our study, total omega 6 PUFAs, monounsaturated fatty acids and SFA were not associated with MPOD measurements. Regarding other factors potentially related to MPOD, we found a significant lower MPOD in ever smokers than in never smokers. Similar associations have been reported previously by some studies (Hammond & CarusoAvery 2000; Delori et al. 2001; Dietzel et al. 2011; Alassane et al. 2016 ) while others found no significant associations with smoking status (Curran-Celentano et al. 2001; Broekmans et al. 2002; Berendschot & van Norren 2005; Yu et al. 2012) . A higher MPOD was significantly associated with a lower BMI in our study, similarly to a number of previous studies (Hammond et al. 2002; Nolan et al. 2007; Dietzel et al. 2011; Alassane et al. 2016) . This association could be explained by the fact that up to 80% of the total carotenoids in the body are located in adipose tissue (Olson 1984) .
Our study has some limitations that need to be considered. We describe cross-sectional associations between omega-3 PUFAs and MPOD. We only have plasma omega-3 PUFAs measurements at baseline; thus, we cannot evaluate associations between changes in plasma omega-3 PUFAs and changes in MPOD. Macular pigment optical density (MPOD) metabolism is influenced by genetic determinants such as genes related to carotenoid transport, uptake and probably AMDrelated genes (Meyers et al. 2013 (Meyers et al. , 2014 . In the present study, we did not assess genetic polymorphisms, preventing us from studying the influence of genetic factors on MPOD measurement in this population. The multivariate analysis showed a difference in MPOD between the two examination centres. This difference might be explained by the fact that the examinations centre measured MPOD using two different devices, although exactly the same model was used by the two centres, to minimize differences. These differences could also be explained by the differences in diet, as participants live in two different French geographical regions with marked differences in dietary habits. Another limitation could come from the measurement technique of macular pigment. The present study measured macular pigment based on autofluorescence imaging using the modified HRA device. Heterochromatic flicker photometry and auto fluorescence imaging are the most suitable and widely used techniques . Several parameters should be taken into account before selecting the device: age of the participants, lens status, ability to respond to psychophysical testing, cost of the machine and fixation ability. Scientists have been debating the advantages and limitations of measurement techniques for over 20 years (Howells et al. 2011; Bernstein et al. 2016 ), conducted studies to compared different methods (Dennison et al. 2013; Creuzot-Garcher et al. 2014) and it is still not agreed which method is the most suitable for measuring macular pigment.
In conclusion, our study suggested that DPA was specifically associated with MPOD in subjects with family history of AMD. These results need to be extended by other studies to identify the underlying mechanisms.
